Repare Therapeutics Inc. (RPTX)

Market Cap	54.41M
Revenue (ttm)	66.52M
Net Income (ttm)	-84.05M
Shares Out	42.51M
EPS (ttm)	-1.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,850
Open	1.280
Previous Close	1.280
Day's Range	1.260 - 1.290
52-Week Range	1.200 - 8.490
Beta	0.88
Analysts	Strong Buy
Price Target	7.00 (+446.88%)
Earnings Date	Feb 26, 2025

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 179
• Stock Exchange: NASDAQ
• Ticker Symbol: RPTX
• Website: https://www.reparerx.com

Financial Performance

In 2023, Repare Therapeutics's revenue was $51.13 million, a decrease of -61.21% compared to the previous year's $131.83 million. Losses were -$93.80 million, 222.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 446.88% from the latest price.

Price Target

$7.0

(446.88% upside)

Analyst Consensus: Strong Buy